We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Simple Blood Test Assesses Prognosis of Advanced Liver Fibrosis in NASH Patients

By LabMedica International staff writers
Posted on 17 Jun 2022
Print article
Image: ELF test has been strongly recommended in 2022 AACE NAFLD guidelines (Photo courtesy of Siemens Healthineers)
Image: ELF test has been strongly recommended in 2022 AACE NAFLD guidelines (Photo courtesy of Siemens Healthineers)

Non-alcoholic fatty liver disease (NAFLD) refers to a spectrum of diseases, from simple fatty liver to more-aggressive nonalcoholic steatohepatitis (NASH). While patients with NASH are more likely to develop progressive disease, which can result in cirrhosis, liver failure, or hepatocarcinoma (HCC), patients without histological evidence of NASH are also at risk. Progressive chronic liver disease (CLD) typically lacks signs and symptoms, with many patients remaining undiagnosed until uncompensated disease presents. Liver fibrosis versus the inflammatory process is recognized as the key driver of pathogenicity in NAFLD/NASH. Early recognition of progressive fibrosis and intervention is key for improved outcomes. Now, a non-invasive blood test that measures three direct markers of fibrosis provides a direct quantitative measure for the assessment of disease progression in patients with advanced fibrosis due to NASH.

The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers (Erlangen, Germany) is the first routine, standardized, direct-biomarker panel for prognostic risk assessment in advanced fibrosis due to NASH. The ELF Test can assess active, dynamic fibrosis rather than the damage it has caused, allowing it to be used as a prognostic marker to identify the patients most at risk of progression to cirrhosis and LREs in patients with advanced fibrosis due to NASH. The ELF score combines three serum biomarkers, namely Hyaluronic acid (HA), Procollagen III N-terminal peptide (PIIINP) and Tissue inhibitors of metalloproteinase (TIMP-1). The three direct markers of the ELF test are complementary and, when combined into an ELF score, provide information that is prognostic for progression to cirrhosis and liver-related events.

Being a blood-based test, the ELF Test can readily support high-volume testing, does not require patient access to specialized imaging equipment or highly trained operators, and generally has lower incidence rates of failure and unreliable results reported for imaging modalities. The ELF Test provides healthcare professionals with access to non-invasive testing through a simple blood test available to all patients, including those with type 2 diabetes mellitus and obesity. It allows them to improve patient care by stratifying advanced NASH patients most at risk of progressing to cirrhosis and liver-related events as well as enhance patient management with a blood test that facilitates more frequent prognostic assessments.

The ELF Test is now included in the 2022 AACE NAFLD Clinical Practice Guidelines to help stratify NASH patients most at risk for progression to cirrhosis. The guideline underscores the value of utilizing direct blood-based biomarkers in the NASH care continuum and represents an opportunity to incorporate preventative care to address the anticipated tsunami of patients from developing cirrhosis or life-threatening liver related events.

Related Links:
Siemens Healthineers 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
POC Laboratory IT Solution
Microbial Infections In-Vitro Diagnostic Solution
Weezion dx

Print article



view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.